Consun Pharmaceutical Group Limited (1681.HK) Stock Analysis
A clinically differentiated nephrology champion with a fast-rising contrast-media franchise—trading cheap despite elite margins, net cash, and shareholder-aligned capital returns.
Overview
Consun Pharmaceutical (1681.HK) is a vertically integrated China pharma group with leadership in two specialized niches: nephrology (modernized TCM for chronic kidney disease) and medical contrast media. Operations are split into the Consun segment (high-margin specialty medicines and imaging agents) and the Yulin segment (revitalized “Chinese Time-honored” OTC TCM). The company’s economics are dominated by flagship Niaoduqing Granules (UCG), notable for multi-center double-blind clinical trial validation and—critically—NRDL Class A reimbursement (100% insurance), supporting durable demand and reducing price sensitivity. FY2025 delivered strong compounding: revenue rose ~15% to ~RMB 3.42bn and profit attributable to shareholders rose ~19% to ~RMB 1.08bn, alongside record margins (gross ~77%). Consun is simultaneously scaling into iodinated contrast media (CT) with new launches aimed at domestic substitution versus multinationals. Financially, it combines high ROE (~25%) with very low leverage (D/E ~5%) and substantial net cash, enabling dividends, buybacks, and defensive resilience.